4a. This clinical research may involve unforeseeable risks to 
the participant (or to the embryo or fetus, if the 
participant is or may become pregnant during treatment) . 
To help prevent injury to unborn children, upon 
recommendation by the attending physician, the 
participants should practice adequate methods of birth 
control throughout the period of their involvement in 
this clinical research study. 
5. POTENTIAL BENEFITS: The use of chemotherapy resistant cells 
will potentially allow the use of higher doses of 
chemotherapy, therefore increasing the chances to destroy the 
ovarian cancer cells. 
6. ALTERNATE PROCEDURES OR TREATMENTS: Participation in this 
marking study is totally optional and other treatment options 
for this disease exist although none are known to alter the 
course of this disease at this time and at this stage of the 
disease. These include conventional dose chemotherapy without 
modified cells. 
UNDERSTANDING OF PARTICIPANTS 
7. I have been given an opportunity to ask any questions 
concerning the investigational drug regimen involved and the 
investigator has been willing to reply to my inquiries. This 
investigational drug regimen will be administered under the 
above numbered, titled and described clinical research 
protocol at this institution. I hereby authorize Dr. 
, the attending physician/ investigator and 
designated associates to administer this investigational drug 
regimen. 
8. I have been told and understand that my participation is 
voluntary. I may decide not to participate, or withdraw my 
consent and discontinue my participation at any time. Such 
action will be without prejudice and there shall be no penalty 
or loss of benefits to which I may otherwise be entitled, and 
I will continue to receive treatment by my physician at this 
institution. 
Should I decide not to participate or withdraw my consent from 
participation in this clinical research, I have been advised 
that I should discuss the consequences or effects of my 
decision with my physician. 
In addition, I understand that the investigator may 
discontinue the clinical research study if, in the sole 
opinion and discretion of the investigator, the study or 
treatment offers me little or no future benefit, or the supply 
of medication ceases to be available or other causes prevent 
continuation of the clinical research study. The investigator 
will notify me should such circumstances arise and my 
Recombinant DNA Research, Volume 17 
[677] 
